HNF1 beta drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC)

Filipa Lopes-Coelho, Sofia Gouveia-Fernandes, Luis Pedro Goncalves, Carolina Nunes, Ines Faustino, Fernanda Silva, Ana Maria Felix de Campos Pinto, Sofia de Azeredo Gaspar Pereira, Jacinta Serpa

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)


Chemoresistance to platinum-based antineoplastic agents is a consistent feature among ovarian carcinomas; however, whereas high-grade serous carcinoma (OSC) acquires resistance during chemotherapy, ovarian clear cell carcinoma (OCCC) is intrinsically resistant. The main objective of this study was to explore, in vitro and in vivo, if hepatocyte nuclear factor 1 beta (HNF1 beta) and glutaminolysis contribute for the resistance of OCCC to carboplatin through the intrinsically increased GSH bioavailability. To disclose the role of HNF1 beta, experiments were also performed in an OSC cell line, which does not express HNF1 beta. Metabolic profiles, GSH quantification, HNF1 beta, and gamma-glutamylcysteine ligase catalytic subunit (GCLC) and modifier subunit (GCLM) expression, cell cycle, and death were assessed in ES2 cell line (OCCC) and OVCAR3 cell line (OSC); HNF1 beta knockdown was performed in ES2 and murine model of subcutaneous and peritoneal OCCC tumors was established to test buthionine sulphoxamine (BSO), as a sensitizer to carboplatin. Glutaminolysis is activated in ES2 and OVCAR3, though ES2 exclusively synthesizes amino acids and GSH. ES2 cells are more resistant to carboplatin than OVCAR3 and the abrogation of GSH production by BSO sensitizes ES2 to carboplatin. HNF1 beta regulates the expression of GCLC, but not GCLM, and consequently GSH production in ES2. In vivo, BSO prior to carboplatin reduces dramatically subcutaneous tumor size and GSH levels, as well as peritoneal dissemination. Our study discloses HNF1 beta as the mediator of intrinsic OCCC chemoresistance and sheds a light to re-explore a cancer adjuvant therapeutic approach using BSO to overcome the lack of efficient therapy in OCCC.
Original languageEnglish
Pages (from-to)4813-4829
Number of pages17
JournalTumor Biology
Issue number4
Publication statusPublished - Apr 2016


Dive into the research topics of 'HNF1 beta drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC)'. Together they form a unique fingerprint.

Cite this